

Supplementary Table S1: Inclusion and exclusion criteria for patients

Inclusion Criteria	Exclusion Criteria
Age >18 years	Prior treatment with anti-PD-1 or anti-CTLA-4 therapy
Capable of providing written and informed consent	Switching to Braf/MEKi during the study course
Advanced malignant melanoma (stage III or IV)	
Treatment with either anti-PD-1 monotherapy or anti-PD-1/anti-CTLA-4 combination therapy according to recommendation of interdisciplinary tumor board	